[ad_1] Shares of Sangamo Therapeutics Inc. fell 13% on Wednesday after results of a half-life trial of its gene-editing candidate SB-913 for the rare metabolic syndrome of Hunter's Syndrome . Two patients …
Read More »Sangamo stock drops 13% before commercialization on half-phasic gene editing test results
